Image via Wikipedia
A new research has suggested that cardiac stem cells – even in elderly and sick patients – could generate new heart muscle and vessel tissue and be used to treat heart failure.
Scientists surgically removed tissue from the muscular wall of the heart’s chambers in 21 patients.
They then isolated and multiplied the cardiac stem cells (CSCs) found there.
Most of the patients had ischemic cardiomyopathy (enlarged and weakened muscle due to coronary artery disease). Eleven also had diabetes. The average age of patients was about 65.
“Regardless of the gender or age of the patient, or of diabetes, we were
Until recently, when a patient suffering a heart attack arrived at a hospital, doctors could open the blocked blood vessel and restore blood flow to prevent further damage. But there was nothing they could do to reverse the harm already done. That damage — scarring that can kill up to 50 percent of the heart — leaves patients with difficulty breathing, loss of energy and the inability to do things such as walk up stairs. Some patients need transplants. And some end up with hearts so weak they die.
The solution: Now doctors can repair that damage. In
Some neck or back injuries that damage the spinal cord can leave a person partially or completely paralyzed.
Now, for the first time, doctors at ASAN Medical Center have confirmed the efficacy of directly injecting a patient’s own autologous stem cells into the injured spinal cord.
After a severe nerve injury to his neck from a car accident in 1998, a patient named Mr. Park, from Chuncheon, was diagnosed with quadriplegia, or complete paralysis.
After being bedridden for eight years, he began receiving stem cell therapy in 2006. Gradually, he started to regain strength in his arms, and finally was able
A first-of-its-kind study is just getting underway at University of Minnesota Physicians Heart at Fairview, in Minneapolis. The FDA-approved trial is designed to test the impact of stem cells on restoring the heart’s muscle function in patients suffering from advanced heart failure. The results of the trial could impact the future of health care in the area of heart disease, and may one day save lives (…)
“This trial is designed for heart failure patients in the end stage of heart failure, with no options for treatment,” explained Ganesh Raveendran, M.D., who is the principal investigator of the clinical trial.
StemCells Inc announced that interim six-month data from the first patient cohort in the Company’s Phase I/II clinical trial of its proprietary HuCNS-SC(R) product candidate (purified human neural stem cells) for chronic spinal cord injury continues to demonstrate a favorable safety profile, and shows considerable gains in sensory function in two of the three patients compared to pre-transplant baselines. The third patient remains stable.
The data was presented by Armin Curt, M.D., principal investigator for the clinical trial, at the 51st Annual Scientific Meeting of the International Spinal Cord Society in London, England. The trial represents the first